Moreover, Alnylam Pharmaceuticals has developed ALN-APP, which fuses a synthetic siRNA targeting APP to a proprietary 2’-O-hexadecyl (C16) lipophilic conjugate, for AD and Cerebral Amyloid Angiopathy. Here, APP is linked to Alzheimer disease.